Evidence map›Paper›PMID 26995353›Full record

ArticleCurrent protocols in chemical biology2016

Hollow-Fiber Methodology for Pharmacokinetic/Pharmacodynamic Studies of Antimalarial Compounds.

Emily Caton, Elizabeth Nenortas, Rahul P Bakshi, Theresa A Shapiro

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current protocols in chemical biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. RNA Polymerase 1 inhibitors against African trypanosomesAntimicrobial agents and chemotherapy · 2026
    Article
  3. NewAntimicrobial agents and chemotherapy · 2022
    Article
  4. Article
  5. Kinetic Driver of Antibacterial Drugs againstAntimicrobial agents and chemotherapy · 2019
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Emily CatonDivision of Clinical Pharmacology, Departments of Medicine and of Pharmacology and Molecular Sciences, and The Johns Hopkins Malaria Research Institute, The Johns Hopkins University, Baltimore, Maryland.
Elizabeth NenortasDivision of Clinical Pharmacology, Departments of Medicine and of Pharmacology and Molecular Sciences, and The Johns Hopkins Malaria Research Institute, The Johns Hopkins University, Baltimore, Maryland.
Rahul P BakshiDivision of Clinical Pharmacology, Departments of Medicine and of Pharmacology and Molecular Sciences, and The Johns Hopkins Malaria Research Institute, The Johns Hopkins University, Baltimore, Maryland.
Theresa A ShapiroDivision of Clinical Pharmacology, Departments of Medicine and of Pharmacology and Molecular Sciences, and The Johns Hopkins Malaria Research Institute, The Johns Hopkins University, Baltimore, Maryland.

Funding

Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
Optimized Combination Antimalarial Drug TherapyR01AI111962 · NIAID · GEORGETOWN UNIVERSITY · PI ROEPE, PAUL D., SULLIVAN, DAVID JOSEPH · 2014 to 2018
$4.9M
Essential PK/PD relationships of antimalarial drugsR01AI095453 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SHAPIRO, THERESA A · 2012 to 2024
$4.8M
NCATS NIH HHS UL1 TR001079NCATS NIH HHS UL1TR001079NIAID NIH HHS R01 AI095453NIAID NIH HHS R01AI095453NIAID NIH HHS R01 AI111962NIAID NIH HHS R01AI111962
6 · The paper itself

Abstract

Knowledge of pharmacokinetic/pharmacodynamic (PK/PD) relationships can enhance the speed and economy of drug development by enabling informed and rational decisions at every step, from lead selection to clinical dosing. For anti-infective agents in particular, dynamic in vitro hollow-fiber cartridge experiments permit exquisite control of kinetic parameters and the study of their consequent impact on pharmacodynamic efficacy. Such information is of great interest for the cost-restricted but much-needed development of new antimalarial drugs, especially since the major human pathogen Plasmodium falciparum can be cultivated in vitro but is not readily available in animal models. This protocol describes the materials and procedures for determining the PK/PD relationships of antimalarial compounds.

Indexed as

AnimalsAntimalarialsArea Under CurveDose-Response Relationship, DrugDrug Screening Assays, AntitumorEquipment DesignPlasmodium falciparumAntimalarialsdrug developmentdynamic PK/PDhollow-fiber cartridge systemmalariapharmacodynamicspharmacokineticsPlasmodium falciparum

Identifiers

PMID26995353
PMCPMC4811375

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.